Celecoxib

證據等級: L5

預測適應症: 10 個

Celecoxib: From Arthritis & Inflammatory Pain to Inflammatory Spondylopathy

One-Sentence Summary

Celecoxib is a selective COX-2 inhibitor (coxib) with established global approvals for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, though it is currently not registered in Singapore. The TxGNN model predicts it may be effective for Inflammatory Spondylopathy (encompassing ankylosing spondylitis and axial spondyloarthritis), with 19 clinical trials — including multiple completed Phase 3 RCTs that directly studied Celecoxib in this indication — and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (global approvals; not currently registered in Singapore)
Predicted New Indication	Inflammatory Spondylopathy
TxGNN Prediction Score	99.80%
Evidence Level	L1
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on Celecoxib's well-characterised pharmacological profile, it is a selective cyclooxygenase-2 (COX-2) inhibitor — the first coxib to reach clinical practice — that blocks the conversion of arachidonic acid to prostaglandin E2 (PGE2), thereby reducing inflammation, pain, and fever while sparing the gastric-protective COX-1 pathway. COX-2 is markedly upregulated at sites of synovial and entheseal inflammation, which are hallmark features of spondyloarthritis.

In inflammatory spondylopathy (including ankylosing spondylitis and axial spondyloarthritis), COX-2–driven PGE2 production at the sacroiliac joints and vertebral end-plates is the central driver of inflammatory back pain, morning stiffness, and progressive bony ankylosis. NSAIDs — and coxibs in particular — have been first-line pharmacotherapy for this condition for over two decades. Celecoxib is approved for ankylosing spondylitis by the FDA and EMA, which independently validates the TxGNN model's prediction for this mechanistic connection.

What makes Celecoxib especially compelling beyond symptom control is emerging evidence of a potentially unique disease-modifying effect. A 2025 systematic analysis (PMID 39757202) demonstrated that Celecoxib — unlike non-selective NSAIDs such as diclofenac — inhibited radiographic bone progression in spondyloarthritis. The proposed mechanism involves suppression of Dickkopf-1 (DKK-1) and Sclerostin, key negative regulators of the Wnt/β-catenin pathway that governs syndesmophyte (bony bridge) formation. This bone-protective signal appears independent of COX inhibition per se, positioning Celecoxib as the only NSAID with credible disease-modification potential in this condition — a finding with direct implications for Singapore patients currently without access to this agent.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00648141	Phase 3	Completed	458	12-week RCT comparing Celecoxib 200 mg QD, 200 mg BID, and Diclofenac 75 mg SR BID in ankylosing spondylitis — core pivotal efficacy and safety data for this indication
NCT00762463	Phase 3	Completed	240	6-week RCT in Chinese AS patients comparing Celecoxib 200 mg QD vs Diclofenac SR, followed by a 6-week extension on Celecoxib 400 mg QD — confirms efficacy in an East Asian population
NCT02758782	Phase 4	Completed	156	CONSUL trial: Celecoxib + Golimumab (anti-TNF) vs Golimumab alone over 2 years in radiographic axSpA — evaluated whether adding an NSAID to biologic therapy slows structural spinal progression
NCT01934933	Phase 4	Completed	150	Celecoxib 200 mg BID vs Etanercept 50 mg QW vs combination in active AS over 54 weeks — MRI SPARCC scoring of sacroiliac joints; establishes Celecoxib's positioning in the biologic era
NCT02528201	Phase 4	Completed	330	12-week confirmatory RCT: Celecoxib 200 mg QD vs 400 mg QD vs Diclofenac TID in AS — designed to confirm results of a prior 6-week trial
NCT03190603	Phase 4	Completed	12	MRI assessment of NSAID effects on sacroiliac joint inflammatory lesions in axSpA — small imaging pilot study
NCT04115098	Phase 2	Terminated	42	N-of-1 trials comparing selective COX-2 inhibitors vs non-selective COX inhibitors in axSpA for disease activity and HRQoL; terminated before full enrolment
NCT03473665	Phase 4	Terminated	9	Pilot RCT of 4 NSAIDs (including Celecoxib) in axSpA comparing pain score change at 4 vs 6 weeks; terminated due to severe under-recruitment — evidence value limited
NCT05164198	Phase 4	Unknown	448	TNF inhibitor dose reduction in stable AS — NSAIDs used as background therapy; Celecoxib is not the primary study intervention
NCT02456363	Phase 2	Unknown	300	Adalimumab + NSAIDs vs Adalimumab alone in AS — observational registry design; limited Celecoxib-specific efficacy data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39757202	2025	Systematic Review / Meta-analysis	BMB Reports	Celecoxib is the only NSAID shown to inhibit bone progression in SpA; proposes a unique mechanism via DKK-1 and Sclerostin suppression, independent of COX inhibition
36800138	2023	RCT	Clinical Rheumatology	Imrecoxib vs Celecoxib in axSpA: both drugs reduced sacroiliac joint inflammation via modulation of bone metabolism markers and angiogenesis, with clinical efficacy correlated to biomarker changes
28626213	2017	RCT	Medical Science Monitor	Imrecoxib vs Celecoxib 200 mg BID in axSpA (n=51, 12 weeks): comparable efficacy; DKK-1 serum levels correlated with MRI imaging score improvements
38228361	2024	RCT (CONSUL trial publication)	Annals of the Rheumatic Diseases	Full publication of CONSUL trial: Celecoxib + Golimumab vs Golimumab monotherapy in r-axSpA — detailed radiographic spinal progression outcomes over 2 years
38832489	2024	RCT	Scandinavian Journal of Rheumatology	Iguratimod + Celecoxib vs placebo + Celecoxib in active axSpA: randomised, double-blind, placebo-controlled assessment of iguratimod add-on efficacy and safety
40028763	2025	Retrospective Cohort	Scandinavian Journal of Rheumatology	Nationwide study comparing CVD and gastrointestinal bleeding risk between Celecoxib and non-selective NSAIDs specifically in AS patients — finds comparable safety profiles
40911151	2025	Umbrella Review	Drugs	Systematic synthesis of all meta-analyses reporting Celecoxib safety in chronic musculoskeletal conditions — most comprehensive safety overview available
25623277	2015	Retrospective Cohort	Arthritis Care & Research	Swedish national population-based cohort: rates of GI, renovascular, and CVD adverse events with etoricoxib, celecoxib, and nsNSAIDs in AS/SpA patients vs unexposed controls
22141388	2011	Narrative Review	Drugs	Comprehensive review of Celecoxib in OA, RA, and AS: established analgesic/anti-inflammatory efficacy and GI tolerability advantage vs nonselective NSAIDs
16960941	2006	RCT	Journal of Rheumatology	Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis — one of the early pivotal AS-specific efficacy studies

Singapore Market Information

Celecoxib is currently not registered in Singapore and has no Health Sciences Authority (HSA) product licences. No product entries are available for tabulation.

Context: Globally, Celecoxib (brand name Celebrex®) is approved by the FDA and EMA for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis (patients ≥2 years), acute pain in adults, and primary dysmenorrhoea. Its absence from the Singapore market represents a regulatory gap, not a lack of evidence.

Safety Considerations

Please refer to the package insert for safety information.

Note from known drug profile: Celecoxib carries class-wide COX-2 inhibitor warnings for increased risk of serious cardiovascular events (myocardial infarction, stroke) — particularly relevant for AS patients who already carry elevated cardiovascular risk. Key contraindications from global labelling include sulfonamide hypersensitivity, aspirin/NSAID allergy (including aspirin-exacerbated respiratory disease), severe heart failure, and post-CABG use. Long-term AS therapy also requires monitoring of renal and hepatic function. These should be confirmed against full prescribing information before any Singapore regulatory submission.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Celecoxib has the strongest evidence profile of all predictions in this pack: two completed Phase 3 RCTs (n=458 and n=240), multiple completed Phase 4 RCTs, and over 20 supporting publications including a 2025 umbrella review and a novel systematic finding that Celecoxib may be the only NSAID to slow structural bone progression in spondyloarthritis. The TxGNN model's prediction is entirely consistent with established global regulatory approvals — making this a high-confidence repurposing candidate specifically for the Singapore market, where Celecoxib is currently inaccessible.

To proceed, the following is needed:

Regulatory pathway: Determine HSA registration route for Celecoxib in Singapore (new drug application or mutual recognition pathway from FDA/EMA approval)
Full prescribing information: Obtain and review complete package insert to populate safety warnings, contraindications, and drug interaction sections (currently data gaps)
Cardiovascular risk assessment: Define patient eligibility criteria given COX-2 inhibitor class cardiovascular warnings and the elevated baseline CV risk in AS patients
Gastrointestinal risk management plan: Evaluate co-prescription of proton pump inhibitors for at-risk patients
Mechanism of action documentation: Retrieve Celecoxib's DrugBank MOA entry to complete the evidence dossier
Paediatric use assessment: If JIA indication is sought alongside AS, confirm paediatric dosing (FDA-approved for ≥2 years) is appropriate for the Singapore context
Local clinical expert consultation: Engage Singapore rheumatologists to assess unmet need and current prescribing practice for AS patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.